Back to search results

Study of Azeliragon for Metastatic Pancreatic Cancer

This study is testing a drug called azeliragon in people with metastatic pancreatic cancer (cancer that has spread to other parts of the body). Azeliragon is a capsule taken by mouth. You might be able to join if you are between 18 and 80 years old, have pancreatic cancer that has spread, and have already been treated with Gemcitabine/Abraxane or FOLFIRINOX-based chemotherapy. The main goal is to find the best dose of azeliragon and see if it's safe. Researchers will also look for early signs that the drug is helping. This study plans to enroll 30 participants, but its current recruitment status is unclear.

Study design
This is an open-label study, meaning both you and the study team will know you are receiving azeliragon. It plans to enroll 30 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, Recommended Phase 2 Dose, is measured at 8 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05766748

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

UNKNOWN
PHASE1Ages 18–80InterventionalTreatment
Cantex Pharmaceuticals
~30 participants
Updated 2024-06-14 on ClinicalTrials.gov
What's tested:Azeliragon

At a glance

Recruiting sites
6 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Recommended Phase 2 Dose
Measured over 8 weeks

Conditions

Metastatic Pancreatic Cancer

Explore related trials

Pancreatic Carcinoma

Where it's being run

6 sites across 6 states
California1
Florida1
Oregon1
Pennsylvania1
South Carolina1
Texas1

Study leadership

  • Andrew Hendifar, MD · PRINCIPAL_INVESTIGATOR · Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

Who to contact

Stephen Marcus, MD
[email protected]
954-315-3660
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

AST (SGOT), ALT (SGPT) ≤ 2.5 × upper limit of normal range (ULN), unless liver metastases are present, then ≤ 5 x ULN is acceptable. Total bilirubin ≤ 1.5 × ULN.
Estimated creatinine clearance of \> 60 mL/min (per Cockroft-Gault formula) 7. Patient has ECOG performance status of ≤ 2 8. Patient has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent Form prior to participation in any study-related activities.

What this trial measures

  • Recommended Phase 2 Dose8 weeks

    Assessment of the recommended phase 2 dose (RP2D) of azeliragon in patients with metastatic pancreatic cancer.